- Companies
- Biomason
Biomason Funding, Investors & Competitors
Biomason has raised $127M across 5 funding rounds, most recently a $37M undisclosed-stage round in January 2025.
Last Biomason funding round
$37M
Undisclosed stage · Jan 2025
Cumulative funding Biomason raised
$127M
across 5 funding rounds
Key investors in Biomason
Novo Holdings
Celesta Capital
2150
Hartree Partners
Martin Marietta Materials
Acorn Innovestments
About Biomason
Biomason is a Durham-headquartered biotechnology company manufacturing biocement using microbial-induced mineralization at ambient temperatures. Since 2012, its processes produce carbon-negative bricks and pavers from aggregate and bacteria, deployed in commercial projects across the United States and Europe including precast bioLITH tiles.
Founded
2012
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Sectors
Biomason Funding History
Biomason has raised a total of $127M across 5 funding rounds.
Biomason's first fundraising round was a $500K seed round in September 2013. The most recent completed round was a $37M undisclosed-stage round in January 2025.
Biomason funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Jan 2025 | Undisclosed stage | - | $37M | Biomason is a Research Triangle Park-based company founded in 2012 that develops biocement, a sustainable construction material grown from microorganisms to replace traditional cement and reduce the concrete industry's carbon emissions, targeting elimination of 25% of emissions by 2030. The company produces biocement used across the US and Europe, bio-based tiles under the Biolith brand, and has demonstrated applications with DARPA and partnerships like H&M Group and IBF. It operates a factory in Denmark and aims to decarbonize concrete, the second most consumed substance responsible for 8% of global emissions via cement. Biomason raised a $65 million Series C round in February 2022, led by 2150 with participation from Celesta Capital, Hartree Partners, Novo Holdings, and Martin Marietta Materials, to accelerate technology development, hiring, commercialization, and broader applications like ready-mix technology. Prior funding included $5 million out of $18 million targeted in 2019, $1.5 million in 2015, and $500,000 earlier, plus loans from the North Carolina Biotechnology Center totaling $800,000. In early 2025, under new CEO Camilo Restrepo, Biomason disclosed raising over $36 million from six investors via a securities filing, part of a planned $50.8 million raise capped amount, with $20.8 million from convertible note conversions and $14.2 million remaining. Investors were not specified but likely include prior backers like 2150, Celesta, Hartree, Martin Marietta, Novo, and Acorn Innovestments. The company has grown to over 100 employees across 55 disciplines, with products installed in North America and Europe, focusing on scaling biocement for global impact in the built environment. |
| Feb 2022 | Series C | 2150 (lead); Novo Holdings; Martin Marietta Materials; Hartree Partners; Celesta Capital | $65M | Biomason, based in Research Triangle Park, North Carolina, develops biocement technology that uses microorganisms to produce cement without high-heat kilns or CO2 emissions from calcination, aiming to eliminate 25% of global concrete industry carbon emissions by 2030. The company produces products like bioLITH precast tiles, which are commercially available, and has installed biocement-powered products across North America and Europe. It has over 100 employees across 55 disciplines and collaborations with DARPA, H&M Group, and IBF for scaling applications. On February 28, 2022, Biomason announced a $65 million Series C funding round led by 2150, with participation from Celesta Capital, Hartree Partners, Novo Holdings, and Martin Marietta Materials. The funds are intended to accelerate development of its proprietary biocement platform for broader applications in the concrete value chain and support commercialization efforts. Biomason had previously raised funds in earlier rounds, including a Series B in 2019, and continued with a grant in November 2022 and a Series D in January 2025 for $36.67M from similar investors including 2150, Celesta Capital, Hartree Partners, Martin Marietta, and Novo Holdings. |
| Dec 2019 | Undisclosed stage | - | $23M | Biomason is a Research Triangle Park-based biotech company developing biocement technology that uses microorganisms to grow sustainable construction materials, aiming to reduce carbon emissions from the cement industry. The company publicly launched in 2019 and had raised prior funding including $1.5M in 2015 and $500,000 in 2013 from unnamed investors, plus debt. This brought total capital raised to about $2M equity and $3.4M debt historically. Early support came from North Carolina Biotechnology Center loans totaling $800k. Biomason's technology enables proprietary manufacturing processes for biocement-based products, licensed for incorporation into existing facilities or on-site production. The 2019 round supported early commercialization efforts as the company looked toward 2020 expansion, including contributions from the founder's savings. By later stages, Biomason grew to over 100 employees across 55 disciplines, installing products in North America and Europe, partnering with DARPA, H&M Group, and IBF. |
| Dec 2015 | Seed | Acorn Innovestments | $2M | - |
| Sep 2013 | Seed | - | $500K | - |
Who has invested in Biomason?
6 investors have backed Biomason across its funding rounds, including Novo Holdings, Celesta Capital, 2150, Hartree Partners, Martin Marietta Materials and Acorn Innovestments.
Lead investors include 2150.
Biomason Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 1 | Participant | Feb 2022 | ||
| 1 | Lead | Feb 2022 | ||
| 1 | Participant | Feb 2022 | ||
| 1 | Participant | Dec 2015 | ||
This data is available for Pro users. Sign up to see all 6 Biomason investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialBiomason Competitors
Biomason competitors include listed companies like CRH, Holcim, Martin Marietta Materials and UltraTech Cement, and private ones like Lafarge India and Tigre.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $37B | $7.6B | $58B | 1.9x | ||
| Publicly listed | $19B | $2.8B | $46B | 2.7x | ||
| Publicly listed | $6.2B | $2.1B | $35B | 5.8x | ||
| Publicly listed | $9.1B | $1.8B | $33B | 3.6x | ||
| Private | - | - | $1.2B | - | ||
| Private | - | $145M | $918M | - |
Biomason Public Comps
Biomason is still privately-owned, but its public comps include CRH, Holcim, Martin Marietta Materials, UltraTech Cement, Vulcan Materials, Heidelberg Materials, Grasim Industries, Amrize, James Hardie Industries and CEMEX.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $37B | $7.6B | 2.0x | 1.9x | 10.0x | 9.4x | |||
| $19B | $2.8B | 2.9x | 2.7x | 19.9x | 11.0x | |||
| $6.2B | $2.1B | 6.7x | 5.8x | 19.8x | 17.1x | |||
| $9.1B | $1.8B | 3.9x | 3.6x | 19.9x | 18.6x | |||
| $7.9B | $2.3B | 4.6x | 4.5x | 15.5x | 15.1x | |||
| $25B | $5.1B | 1.6x | 1.5x | 7.5x | 7.0x | |||
| $18B | $2.6B | 2.7x | 10.7x | 18.9x | 196.9x | |||
| $12B | $2.8B | 2.3x | 2.2x | 9.8x | 8.9x | |||
This data is available for Pro users. Sign up to see all Biomason competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Biomason
| When was Biomason founded? | Biomason was founded in 2012. |
| Where is Biomason headquartered? | Biomason is headquartered in Durham, NC, United States. |
| Is Biomason publicly listed? | No, Biomason is a private, VC-backed company. |
| How much funding has Biomason raised? | Biomason has raised $127M across 5 funding rounds. |
| What was Biomason's last funding round? | Biomason's last funding round was a $37M undisclosed-stage round in January 2025. |
| Who are Biomason's investors? | Biomason's investors include Novo Holdings, 2150, Martin Marietta Materials, Acorn Innovestments, Hartree Partners and Celesta Capital. |
| Which companies are comparable to Biomason? | Companies comparable to Biomason include CRH, Holcim, Martin Marietta Materials, UltraTech Cement, Lafarge India and Tigre. |
See companies similar to Biomason
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




